On arrête plus Exothera et le groupe Univercells !!! 🚀👏🏻 sambrinvest.be/fr/actualites/…

‼️Exothera Earns GMP Certification for #Jumet Facility‼️ Accreditation further extends CDMO's #viralvector manufacturing capacity ➡️ow.ly/1FZv50Ir9SC #pharma #pharmanews #lifesciences #pharmamanufacturing

🗣️ Montse Daban, Scientific and International Relations Director at #Biocat, has participated today as a panelist at the session "Perspectives on the pan-European manufacturing landscape" together with Jerôme Fabiano from EIT Health France & Thibault Jonckheere from Exothera.

Plongeon dans l’univers des #biotechs au travers de 3 filiales d’UniverCell 's, entreprise mondiale des sciences de la vie implantée en #Wallonie et dont l’objectif est d’élargir l’accès aux médicaments biologiques & les rendre plus abordables 💊 #Quantoom Exothera

[PRESS RELEASE] Rokote Laboratories and Exothera will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials! Read the press release: bit.ly/3JXgx2C #GMPManufacturing #ViralVaccines #GeneTherapy

[PRESS RELEASE] This collaboration will be financed by a €3 million grant awarded by the Bill & Melinda Gates Foundation to develop and deliver new low-cost vaccines based on ReiThera’s GRAd technology platform. Read the Press Release: bit.ly/3riG2nQ

This morning @ #CGMED22, we have company presentations from Anocca, Luminary Tx, PDC*line Pharma, Fraunhofer IZI, Avectas, Exothera, Sangamo Therapeutics, Autolus Tx, Astellas Pharma US, GenSight Biologics, EG 427, MARKEN, Quell Tx, & @Enzyvant. We're excited to hear from these industry leaders!

[PRESS RELEASE]  This fully integrated platform will ensure faster, more cost-effective production of viral vector-based therapeutics (for gene therapy, vaccines, and oncolytic viruses for cancer treatment) at scale! ► READ THE PRESS RELEASE: bit.ly/3NAae6T

[PRESS RELEASE] This collaboration among @EXOTHERA, LogicBio Therapeutics, and @Polyplus_Transf aims to develop a highly scalable and cost-effective AAV manufacturing platform! Read the press release: bit.ly/3zEeMFe #GeneTherapy #vaccines #AAVManufacturing

We’re delighted to announce Exothera will be developing a large-scale manufacturing process for the clinical development of VALO-D102, our proprietary oncolytic adenovirus which forms part of our PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) platform.

Exothera announces the appointment of Darren Leva as Chief Business Officer hubs.li/Q01zLbTn0 #CDMO #CBO #Biotherapeutics

We are thrilled to welcome Darren Leva as our new Chief Business Officer. With his extensive experience in the biotech industry and a proven track record of driving growth, he is the perfect addition to our team. 😀👍 READ THE PRESS RELEASE: bit.ly/3XVtXmL

Remedium and Exothera partner on scale-up and demonstration runs for AAV2-FGF18 hubs.li/Q01HD2lN0 #Biotechnology #Osteoarthritis #GeneTherapy #CDMO

[PRESS RELEASE] We are thrilled to announce this new collaboration in which Exothera will demonstrate the industrialization potential of Remedium Bio's AAV-based gene therapy for the treatment of Osteoarthritis! Click here to discover the press release: bit.ly/40sAzcY

[PRESS RELEASE] Exothera Nucleic Acids will be the world’s first CDMO with access to Quantoom Biosciences’s revolutionary Nfinity™ platform for the continuous production of RNA which Exothera will offer as a service! Discover the press release: bit.ly/3Abb2de

Exothera announces a strategic partnership with Quantoom Biosciences and launches a new business unit for the development and production of RNA #RNAproduction #CDMO tinyurl.com/5n8twme8

As Chief Technology Officer, Patrick Thiaville will help to accelerate the delivery of high-quality development and manufacturing services for the next generation of RNA therapies! 👏👍 Read the Press Release: exothera.world/exothera-nucle…

Exothera Viral Vectors will manufacture Meissa Vaccines’s MV-012-968 vaccine candidate, an intranasal live attenuated RSV aiming to protect infants and young children from respiratory syncytial virus (RSV). Read the Press Release: shorturl.at/cT356

Member news! Meissa Vaccines enters into cGMP manufacturing agreement with Exothera for pediatric RSV vaccine candidate for phase 2 clinical trials. tinyurl.com/4an4xzm7